Management of Adverse Events From Cancer Immunotherapy: Resources for Emergency Medicine Specialists

The goal of this activity is to improve the knowledge, competence, and performance of physicians and other clinicians who provide emergency care for patients with cancer who are experiencing an immune-related adverse event from immune checkpoint inhibitor therapy.

Target Audience

This program is intended for emergency medicine specialist physicians and other healthcare providers who care for patients with cancer who are receiving treatment with immune checkpoint inhibitors and are experiencing immune-related symptoms.

Learning Objectives

At the conclusion of the program, participants should be able to:

  • Describe the different immune checkpoint inhibitors and their current indications for the treatment of patients with cancer
  • Recognize the wide spectrum of potential immune-related adverse events (irAEs) associated with different immune checkpoint inhibitors based on their mechanism of action.
  • Apply knowledge regarding the unique timing and presentation of irAEs to the timely identification of irAEs in patients with cancer receiving immune checkpoint inhibitors
  • Assess and differentiate emergent versus nonemergent medical conditions that can occur with cancer immunotherapy and an activated immune system 
  • Manage specific types and grades of immune-related adverse events in patients with cancer receiving immune checkpoint inhibitor therapy
  • Practice effective coordination with oncology providers to ensure continuity of care for immune-related adverse events
Additional information
Supporters: 

This program is supported by educational grants from EMD Serono, Inc. and Pfizer Inc.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
04/19/2019
Course expires: 
04/19/2020
Cost:
$0.00

John A. Thompson, MD
Professor of Medicine
Division of Medical Oncology
University of Washington
Seattle, Washington

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

The faculty, NCCN staff, and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Faculty Disclosures

John A. Thompson, MD, has disclosed that he has received consulting fees from AstraZeneca, Calithera, and Synthorx.

Staff Disclosures

The activity planning staff listed below discloses no relevant financial relationships:
CCO: Megan Cartwright, PhD; Krista Marcello; Timothy Quill, PhD
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CHCP

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jillian Scavone, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Accreditation Period

Course opens: 
04/19/2019
Course expires: 
04/19/2020

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: